Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Advertisement

Advertisement




Sep
20
Today In Oncology
Losing Weight and Breast Cancer Risk? The GLP-1 Question
TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer
FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer
Independent Validation Supports Prognostic Value of Computational TILs in Triple-Negative Breast Cancer
NCCN Releases New Guideline for Patients and Caregivers: Older Adults With Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo